TABLE 1.
Demographic Characteristics, Clinical Variables, and Perceived Risk of Contracting SARS-CoV-2 at Enrollment
| Variable | Value, % |
|---|---|
| Women | 83 |
| Age, mean, (range), y | 50 (22–87) |
| Race | |
| Asian | 8 |
| Black | 10 |
| White | 82 |
| Latino | 13 |
| Major comorbiditya | 43 |
| Diagnosis | |
| Systemic lupus erythematosus | 28 |
| Rheumatoid arthritis | 27 |
| Undifferentiated connective tissue disorder | 7 |
| Psoriatic arthritis | 7 |
| Sjögren syndrome | 4 |
| Mixed connective tissue disorder | 3 |
| Otherb | 23 |
| Duration of diagnosis, mean (range), y | 11 (.5–57) |
| Medications for rheumatic disease | |
| Conventional disease modifying anti‐rheumatic drugs | |
| Hydroxychloroquine | 50 |
| Glucocorticoids | 49 |
| Methotrexate | 16 |
| Azathioprine | 9 |
| Mycophenolate mofetil | 5 |
| Biologic disease modifying anti‐rheumatic drugs | |
| Tumor necrosis factor inhibitor | 17 |
| Interleukin inhibitor | 11 |
| B-cell activating factor inhibitor | 11 |
| B-cell CD20 monoclonal antibody | 9 |
| T-cell costimulatory signal inhibitor | 3 |
| Janus kinase (JAK) inhibitor | 3 |
| Perceive risk of contracting SARS-CoV-2 compared with general population | |
| Very much greater risk | 53 |
| Somewhat greater risk | 35 |
| Little more risk or not increased risk | 8 |
| Less risk or do not know | 3 |
| Perceive medications increase risk of contracting SARS-CoV-2 | |
| Definitely | 57 |
| Probably | 5 |
| Not really | 20 |
| Protective | 9 |
| Do not know | 9 |
aAccording to the Charlson Comorbidity Index.
bSpondyloarthritis, polymyalgia rheumatica, antiphospholipid syndrome/SLE, ankylosing spondylitis, small vessel vasculitis, scleroderma, Churg-Strauss syndrome, Still disease, overlap syndromes.